Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CNTB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| CBP-201 | Atopic Dermatitis | Phase 3 · NCT05614817 | Withdrawn |
| NACL 0.9% | Patency of the Ductus Arteriosus | Phase 2/3 · NCT04459117 | Completed |
| Double-blind 200 mg imsidolimab | Moderate to Severe Ulcerative Colitis | Phase 2 · NCT04700449 | Completed |
| Open-label CBP-307 | Moderate to Severe Ulcerative Colitis | Phase 2 · NCT04700449 | Completed |
| Rademikibart | Asthma Acute | Phase 2 · NCT07705737 | Recruiting |
| CBP-174 | Healthy Adult Subjects | Phase 1 · NCT04811469 | Completed |
| CBP-307 | Autoimmune Diseases | Phase 1 · NCT04818229 | Completed |
| Moxifloxacin | Autoimmune Diseases | Phase 1 · NCT04818229 | Completed |
| Reference drug (R): CBP-201 injection (vial… | Healthy Adult Subjects | Phase 1 · NCT05917782 | Completed |
| Test drug (T1): CBP-201 injection (pre-filled… | Healthy Adult Subjects | Phase 1 · NCT05917782 | Completed |
Also used in these trials (approved or third-party drugs, not CNTB's own candidates): Acetaminophen.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CNTB holds $24.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $14M/quarter from operations, an estimated runway of 5.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 87 · High
These conditions raise substantial doubt as to our ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CNTB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| James Huang Director |
Insider | 13,310,000 | 20.64% | 2026-05-29 |
| Panacea Innovation Limited | 5%+ holder (13D) | 13,160,000 | 20.41% | 2026-03-31 |
| Wubin Pan | 5%+ holder (13G) | 6,026,813 | 9.35% | 2026-04-14 |
| Braden M Leonard | 5%+ holder (13G) | 4,264,400 | 6.61% | 2026-09-30 |
| BML Capital Management, LLC | Institution (13F) | 3,864,400 | 5.99% | 2026-09-30 |
| Ikarian Capital, LLC | Institution (13F) | 2,235,534 | 3.47% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 1,754,064 | 2.72% | 2026-09-30 |
| Blackrock Inc. | Institution (13F) | 1,021,129 | 1.58% | 2026-09-30 |
| Richmond Brothers, Inc. | Institution (13F) | 833,333 | 1.29% | 2026-09-30 |
| Perceptive Advisors Llc | Institution (13F) | 792,696 | 1.23% | 2026-09-30 |
| Adar1 Capital Management, LLC | Institution (13F) | 700,000 | 1.09% | 2026-09-30 |
| Quinn Opportunity Partners, LLC | Institution (13F) | 505,000 | 0.78% | 2026-09-30 |
Share count 64,488,293 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-30 filed 2026-10-01 |
Xanthopoulos Kleanthis Gabriel |
Award (A) | 5,000 | – | 91,554 |
| 2026-09-30 filed 2026-10-01 |
LIU JEAN I |
Award (A) | 8,984 | – | 20,763 |
| 2026-06-30 filed 2026-07-01 |
Xanthopoulos Kleanthis Gabriel |
Award (A) | 3,738 | – | 86,554 |
| 2026-06-30 filed 2026-07-01 |
LIU JEAN I |
Award (A) | 6,718 | – | 11,779 |
| 2026-05-29 filed 2026-06-02 |
Huang James |
Purchase (P) | 150,000 | $2.48 | 13,310,000 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CNTB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →